KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Expenditures (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Capital Expenditures for 16 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 101.57% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 34.84% decrease, with the full-year FY2025 number at $7.0 million, down 34.84% from a year prior.
  • Capital Expenditures was $6.2 million for Q4 2025 at Halozyme Therapeutics, up from -$1.7 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $14.8 million in Q4 2023 to a low of -$9.2 million in Q3 2023.
  • A 5-year average of $2.0 million and a median of $770500.0 in 2021 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 3581.88% in 2023; the steepest drop was 1014.78% in 2023.
  • Halozyme Therapeutics' Capital Expenditures stood at $158000.0 in 2021, then skyrocketed by 1383.54% to $2.3 million in 2022, then surged by 529.74% to $14.8 million in 2023, then crashed by 79.32% to $3.1 million in 2024, then surged by 101.57% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Capital Expenditures are $6.2 million (Q4 2025), -$1.7 million (Q3 2025), and $2.0 million (Q2 2025).